MP 8.01.34
Hematopoietic Cell Transplantation for Solid Tumors of Childhood

DISCLAIMER/INSTRUCTIONS FOR USE
Medical Policy provides general guidance for applying Blue Cross of Idaho benefit plans (for purposes of Medical Policy, the terms “benefit plan” and “member contract” are used interchangeably). Coverage decisions must reference the member specific benefit plan document. The terms of the member specific benefit plan document may be different than the standard benefit plan upon which this Medical Policy is based. If there is a conflict between a member specific benefit plan and the Blue Cross of Idaho’s standard benefit plan, the member specific benefit plan supersedes this Medical Policy. Any person applying this Medical Policy must identify member eligibility, the member specific benefit plan, and any related policies or guidelines prior to applying this Medical Policy. Blue Cross of Idaho Medical Policies are designed for informational purposes only and are not an authorization, explanation of benefits or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the member specific benefit plan coverage. Blue Cross of Idaho reserves the sole discretionary right to modify all its Policies and Guidelines at any time. This Medical Policy does not constitute medical advice.

POLICY

Autologous hematopoietic cell transplantation may be considered medically necessary for:

• initial treatment of high-risk neuroblastoma,
• recurrent or refractory neuroblastoma,
• initial treatment of high-risk Ewing sarcoma,
• recurrent or refractory Ewing sarcoma, and
• metastatic retinoblastoma.

Tandem autologous hematopoietic cell transplantation may be considered medically necessary for high-risk neuroblastoma.

Autologous hematopoietic cell transplantation is considered investigational as initial treatment of low- or intermediate-risk neuroblastoma, initial treatment of low- or intermediate-risk Ewing sarcoma, and for other solid tumors of childhood including, but not limited to the following:

• rhabdomyosarcoma
• Wilms tumor
• osteosarcoma
• retinoblastoma without metastasis.

Tandem autologous hematopoietic cell transplantation is considered investigational for the treatment of all other types of pediatric solid tumors except high-risk neuroblastoma, as noted above.

Allogeneic (myeloablative or nonmyeloablative) hematopoietic cell transplantation is
considered investigational for treatment of pediatric solid tumors.

Salvage allogeneic hematopoietic cell transplantation for pediatric solid tumors that relapse after autologous transplant or fail to respond is considered investigational.

POLICY GUIDELINES

This policy addresses peripheral neuroblastoma arising from the peripheral nervous system (ie, neuroblastoma, ganglioneuroblastoma, ganglioneuroma).

Hematopoietic cell transplantation refers to any source of stem cells, ie, autologous, allogeneic, syngeneic, or umbilical cord blood.

Relapse is defined as tumor recurrence after a prior complete response.

Primary refractory disease is defined as a tumor that does not achieve a complete remission after initial standard-dose chemotherapy.

Coding

CPT centralized codes describing allogeneic and autologous hematopoietic stem cell support services to the hematology section (CPT 38204-38242). Not all codes are applicable for each high-dose chemotherapy/stem cell support procedure. For example, Plans should determine if cryopreservation is performed. A range of codes describes services associated with cryopreservation, storage, and thawing of cells (38207-38215):

CPT 38208 and 38209 describe thawing and washing of cryopreserved cells

CPT 38210-38214 describe certain cell types being depleted

CPT 38215 describes plasma cell concentration.

BENEFIT APPLICATION

BlueCard/National Account Issues

The following considerations may supersede this policy:

- State mandates requiring coverage for autologous bone marrow transplantation offered as part of clinical trials of autologous bone marrow transplantation approved by the National Institutes of Health.
- Some plans may participate in voluntary programs offering coverage for patients participating in National Institutes of Health-approved clinical trials of cancer chemotherapies, including autologous bone marrow transplantation.
- Some contracts or certificates of coverage (eg, Federal Employee Program) may include specific conditions in which autologous bone marrow transplantation would be considered eligible for coverage.

BACKGROUND

Solid Tumors of Childhood

Solid tumors of childhood arise from mesodermal, ectodermal, and endodermal cells of origin. Some common solid tumors of childhood are neuroblastoma, Ewing sarcoma/Ewing sarcoma family of tumors (ESFT), Wilms tumor, rhabdomyosarcoma, osteosarcoma, and retinoblastoma.

General Treatment
The prognosis for pediatric solid tumors has improved more recently, mostly due to the application of multiagent chemotherapy and improvements in local control therapy (including aggressive surgery and advancements in radiotherapy). However, patients with metastatic, refractory, or recurrent disease continue to have poor prognoses, and these “high-risk” patients are candidates for more aggressive therapy, including autologous hematopoietic cell transplantation (HCT), to improve event-free survival and overall survival.

Descriptions of pediatric-onset solid tumors addressed herein are as follows.

Peripheral Neuroblastoma

Neuroblastoma is the most common extracranial solid tumor of childhood, with approximately 90% of cases presenting in children younger than 5 years of age. These tumors originate where sympathetic nervous system tissue is present, within the adrenal medulla or paraspinal sympathetic ganglia, but have diverse clinical behavior depending on a variety of risk factors.

Patients with neuroblastoma are stratified into prognostic risk groups (low, intermediate, high) that determine treatment plans. Risk variables include age at diagnosis, clinical stage of disease, tumor histology, and certain molecular characteristics, including the presence of the MYCN oncogene. Tumor histology is categorized as favorable or unfavorable, according to the degree of tumor differentiation, the proportion of tumor stromal component, and index of cellular proliferation. It is well-established that MYCN amplification is associated with rapid tumor progression and a poor prognosis, even in the setting of other coexisting favorable factors. Loss of heterozygosity (LOH) at chromosome arms 1p and 11q frequently occurs in neuroblastoma. Although 1p LOH is associated with MYCN amplification, 11q is usually found in tumors without this abnormality. Some recent studies have shown that 1p LOH and unbalanced 11q LOH are strongly associated with outcome in patients with neuroblastoma, and both are independently predictive of worse progression-free survival in patients with low- and intermediate-risk disease. Although the use of these LOH markers in assigning treatment in patients is evolving, they may prove useful to stratify treatment.

In the early 1990s, a uniform clinical staging system based on surgical resectability and distant spread, the International Neuroblastoma Staging System, was adopted by pediatric cooperative groups (see Table 1).

Table 1. International Neuroblastoma Staging System

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Localized tumor with complete gross excision, with or without microscopic residual disease; lymph nodes negative for tumor</td>
</tr>
<tr>
<td>2A</td>
<td>Localized tumor with incomplete gross excision; lymph nodes negative for tumor</td>
</tr>
<tr>
<td>2B</td>
<td>Localized tumor with or without complete gross excision, with ipsilateral lymph nodes positive for tumor</td>
</tr>
<tr>
<td>3</td>
<td>Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration or by lymph node involvement</td>
</tr>
<tr>
<td>4</td>
<td>Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs, except as defined for stage 4S</td>
</tr>
</tbody>
</table>
Localized primary tumor as defined for stage 1, 2A, or 2B, with dissemination limited to skin, liver, and/or bone marrow (marrow involvement less than 10%), limited to children younger than 1 year of age.

The low-risk group includes patients younger than one year of age with stage 1, 2, or 4S with favorable histopathologic findings and no MYCN oncogene amplification. High-risk neuroblastoma is characterized by age older than one year, disseminated disease, MYCN oncogene amplification, and unfavorable histopathologic findings.

The International Neuroblastoma Risk Group (2009) proposed a revised staging system, which incorporated pretreatment imaging parameters instead of surgical findings (see Table 2).

**Table 2. International Neuroblastoma Risk Group Staging System**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L1</td>
<td>Localized tumor not involving vital structures as defined by the list of Image-Defined Risk Factors and confined to one body compartment</td>
</tr>
<tr>
<td>L2</td>
<td>Locoregional tumor with presence of one or more Image-Defined Risk Factors</td>
</tr>
<tr>
<td>M</td>
<td>Distant metastatic disease (except stage MS)</td>
</tr>
<tr>
<td>MS</td>
<td>Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow</td>
</tr>
</tbody>
</table>

**Treatment**

In general, most patients with the low-stage disease have excellent outcomes with minimal therapy; and with International Neuroblastoma Staging System stage-1 disease, most patients can be treated by surgery alone. Most infants, even with disseminated disease, have favorable outcomes with chemotherapy and surgery.

For intermediate-risk disease, moderately intensive multiagent chemotherapy is the mainstay of therapy. Surgery is needed to obtain a diagnosis, and the extent of resection necessary to obtain an optimal outcome is not established. Patients at high-risk have historically had very low (<15%) long-term overall survival. Current therapy for high-risk disease typically includes an aggressive multimodal approach with chemotherapy, surgical resection, and radiotherapy.

Treatment of recurrent disease is determined by the risk group at diagnosis and the extent of disease and age of the patient at recurrence.

**Ewing Sarcoma Family of Tumors**

ESFT encompasses a group of tumors that share some degree of neuroglial differentiation and a characteristic underlying molecular pathogenesis (chromosomal translocation). The translocation usually involves chromosome 22 and results in fusion of the EWS gene with one of the members of the ETS (E26 transformation-specific) family of transcription factors, either FLI1 (90%-95%) or ERG (5%-10%). These fusion products function as oncogenic aberrant transcription factors. Detection of these fusions is considered to be specific for the ESFT and helps further validate diagnosis. Included in ESFT are “classic” Ewing sarcoma of bone, extraosseous Ewing, peripheral primitive neuroectodermal tumor, and Askin tumors (chest wall).

Most commonly diagnosed in adolescence, ESFT can be found in bone (most commonly) or soft tissue; however, the spectrum of ESFT has also been described in various organ systems. Ewing is the second
most common primary malignant bone tumor. The most common primary sites are the pelvic bones, the long bones of the lower extremities, and the bones of the chest wall.

**Treatment**

Current therapy for Ewing sarcoma typically includes induction chemotherapy, followed by local control with surgery and/or radiotherapy (dependent on tumor size and location), followed by adjuvant chemotherapy. Multiagent chemotherapy, surgery, and radiotherapy have improved progression-free survival rates in patients with the localized disease to 60% to 70%. The presence of metastatic disease is the most unfavorable prognostic feature, and the outcome for patients presenting with metastatic disease is poor, with 20% to 30% progression-free survival. Other adverse prognostic factors that may categorize a patient as having “high-risk” Ewing are tumor location (eg, patients with pelvic primaries have worse outcomes), larger tumor size, and older age of the patient. However, “high-risk” Ewing has not always been consistently defined in the literature.

**Rhabdomyosarcoma**

Rhabdomyosarcoma, the most common soft tissue sarcoma of childhood, shows skeletal muscle differentiation. The most common primary sites are the head and neck (eg, parameningeal, orbital, pharyngeal), genitourinary tract, and extremities.

**Treatment**

Specific treatment is based on tumor location, resection, and node status, and may involve surgery, radiotherapy, and chemotherapy. Five-year survival rates for rhabdomyosarcoma increased between 1975 and 2010 from 53% to 67% in children younger than 15 years and from 30% to 51% in 15- to 19-year-olds. Approximately 15% of children present with metastatic disease, and despite the introduction of new drugs and intensified treatment, the 5-year survival is 20% to 30% for this “high-risk” group. Similarly, postrelapse mortality is very high. The prognosis of the metastatic disease is affected by tumor histology, age at diagnosis, the site of metastatic disease, and the number of metastatic sites.

**Wilms Tumor**

Wilms tumor is the most common primary malignant renal tumor of childhood. In the United States, Wilms tumor is staged using the National Wilms Tumor Study system, which is based on surgical evaluation before chemotherapy (see Table 3).

### Table 3. National Wilms Tumor Study Staging

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
</table>
| I     | (a) Tumor is limited to the kidney and completely excised;  
(b) The tumor was not ruptured before or during removal;  
(c) The vessels of the renal sinus are not involved beyond 2 mm  
(d) There is no residual tumor apparent beyond the margins of excision |
| II    | (a) Tumor extends beyond the kidney but is completely excised  
(b) No residual tumor is apparent at or beyond the margins of excision  
(c) Tumor thrombus in vessels outside the kidney is stage II if the thrombus is removed en bloc |
### Hematopoietic Cell Transplantation for Solid Tumors of Childhood

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>Residual tumor confined to the abdomen:</td>
</tr>
<tr>
<td></td>
<td>(a) Lymph nodes in the renal hilum, the periaortic chains, or beyond are found to contain tumor</td>
</tr>
<tr>
<td></td>
<td>(b) Diffuse peritoneal contamination by the tumor</td>
</tr>
<tr>
<td></td>
<td>(c) Implants are found on the peritoneal surfaces</td>
</tr>
<tr>
<td></td>
<td>(d) Tumor extends beyond the surgical margins either microscopically or grossly</td>
</tr>
<tr>
<td></td>
<td>(e) Tumor is not completely resectable because of local infiltration into vital structures</td>
</tr>
<tr>
<td>IV</td>
<td>Presence of hematogenous metastases or metastases to distant lymph nodes</td>
</tr>
<tr>
<td>V</td>
<td>Bilateral renal involvement at the time of initial diagnosis</td>
</tr>
</tbody>
</table>

Adapted from Metzger and Dome (2005).

### Treatment

In the United States, National Wilms Tumor Study and Children’s Oncology Group protocols are based on primary resection for unilateral tumors, followed by escalating levels of chemotherapy and radiotherapy depending on tumor stage and other prognostic factors. Tumor histology, tumor stage, molecular and genetic markers (e.g., LOH at chromosome 16q), and age (>2 years) are all associated with increased risks of recurrence and death. Wilms tumors are highly sensitive to chemotherapy and radiotherapy, and current cure rates exceed 85%. Between 10% and 15% of patients with favorable histology and 50% of patients with anaplastic tumors, experience tumor progression or relapse.

Similar risk-adapted strategies are being tested for the 15% of patients who experience a relapse. Success rates after relapse range from 25% to 45%. For patients with adverse prognostic factors (histologically anaplastic tumors, relapse <6 to 12 months after nephrectomy, second or subsequent relapse, relapse within the radiation field, bone or brain metastases), the event-free survival rate is less than 15%.

### Osteosarcoma

Osteosarcoma is a primary malignant bone tumor and the most common bone cancer in children and adolescents; it is characterized by infiltration of bone or osteoid by the tumor cells. Peak incidence occurs around puberty, most commonly in long bones such as the femur or humerus. Osteosarcomas are characterized by variants in the TP53 tumor suppressor gene.

The prognosis of osteosarcoma has greatly improved, with 5-year survival rates increasing between 1975 and 2010 from 40% to 76% in children younger than 15 years and from 56% to 66% in 15- to 19-year-olds. Prognostic factors for patients with localized disease include site and size of the primary tumor, the presence of metastases at the time of diagnosis, resection adequacy, and tumor response to neoadjuvant chemotherapy.

### Treatment

For patients with recurrent osteosarcoma, the most important prognostic factor is surgical resectability. There is a 5-year survival rate of 20% to 45% in patients who had a complete resection of metastatic pulmonary tumors and a 20% survival rate for patients with metastatic tumors at other sites.
Retinoblastoma

Retinoblastoma is the most common primary tumor of the eye in children. It may occur as a heritable (25%-30%) or nonheritable (70%-75%) tumor. Cases may be unilateral or bilateral, with bilateral tumors almost always being the heritable type.

Treatment

Treatment options depend on the extent of disease. Retinoblastoma is usually confined to the eye, and with current therapy has a high cure rate. However, once disease spreads beyond the eye, survival rates drop significantly; five-year disease-free survival is reported to be less than 10% in those with the extraocular disease, and stage 4B disease (ie, disease metastatic to the central nervous system) has been lethal in virtually all cases reported.

The strategy for nonmetastatic disease depends on the disease extent but may include focal therapies (eg, laser photocoagulation, cryotherapy, plaque radiotherapy), intravitreal chemotherapy, intra-arterial chemotherapy, systemic chemotherapy, enucleation, or a combination.

For metastatic disease, intensive multimodal therapy with high-dose chemotherapy, with or without radiotherapy, is standard care.

Notes: Other solid tumors of childhood include germ cell tumors, which are considered in evidence review 8.01.35. For solid tumors classified as embryonal tumors arising in the central nervous system, see evidence review 8.01.28 and for central nervous system tumors derived from glial cells (ie, astrocytoma, oligodendroglioma, or glioblastoma multiforme) see evidence review 8.01.31.

Hematopoietic Cell Transplantation

HCT is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs, with or without whole body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is critical for achieving a good outcome of allogeneic HCT. Compatibility is established by typing of human leukocyte antigens using cellular, serologic, or molecular techniques. Human leukocyte antigens refer to the tissue type expressed at class I and class II loci on chromosome 6. Depending on the disease being treated, an acceptable donor (except umbilical cord blood) will match the patient at all or most human leukocyte antigens loci.

Cord blood is discussed in detail in evidence review 7.01.50.

Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.
This evidence review was created in April 2000 and has been updated regularly with searches of the MEDLINE database. The most recent literature update was performed through October 29, 2018.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Peripheral Neuroblastoma

Single Autologous Hematopoietic Cell Transplantation

Clinical Context and Therapy Purpose

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with high-risk or relapsed peripheral neuroblastoma.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest are individuals with high-risk or relapsed peripheral neuroblastoma.

Interventions

The therapy being considered is single autologous HCT.

Comparators

Comparators of interest include chemotherapy, targeted therapy, surgery, and radiotherapy.

Outcomes

The general outcomes of interest are overall survival (OS), disease-specific survival (DSS), treatment-related mortality (TRM), and treatment-related morbidity.

Timing
Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

**Setting**

Patients with high-risk or relapsed peripheral neuroblastoma are managed by oncologists in both the inpatient and outpatient clinical settings.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
d. Studies with duplicative or overlapping populations were excluded.

**Systematic Reviews**

A 2013 Cochrane review evaluated high-dose chemotherapy (HDC) and autologous HCT for high-risk neuroblastomas. Reviewers identified 3 RCTs that included 739 children with high-risk neuroblastoma (Matthay et al [1999], Berthold et al [2005], Pritchard et al [2005], detailed in the Randomized Controlled Trial section below). The review was updated in 2015 with no new studies identified, although a manuscript reporting additional follow-up data for one of these RCTs was noted. The primary objective was to compare the efficacy of myeloablative therapy with conventional therapy. Selected studies all used the age of one year as the cutoff point for pretreatment risk stratification. A statistically significant difference in event-free survival (EFS) was observed in favor of myeloablative therapy over conventional chemotherapy or no further treatment (3 studies, 739 patients; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67 to 0.90). A statistically significant difference in OS was reported in favor of myeloablative therapy over conventional chemotherapy or no further treatment (2 studies, 360 patients; HR=0.74; 95% CI, 0.57 to 0.98). When additional follow-up data were included in analyses, the difference in EFS remained statistically significant (3 studies, 739 patients; HR=0.79; 95% CI, 0.70 to 0.90), but the difference in OS was no longer statistically significant (2 studies, 360 patients; HR=0.86; 95% CI, 0.73 to 1.01). Meta-analysis of secondary malignant disease and treatment-related death did not show any statistically significant differences between treatment groups. Data from 1 study (379 patients) showed a significantly higher incidence of renal effects, interstitial pneumonitis, and veno-occlusive disease in the myeloablative group compared with conventional chemotherapy, whereas for serious infections and sepsis, no significant differences between treatment groups were identified. No information on the quality of life was reported.

**Randomized Controlled Trials**

Three well-designed, randomized trials have assessed autologous HCT in the treatment of high-risk neuroblastoma. Matthay et al (1999) randomized 129 children with high-risk neuroblastoma to a combination of myeloablative chemotherapy, total body irradiation, and transplantation of autologous bone marrow and compared their outcomes with those of 150 children randomized to intensive nonmyeloablative chemotherapy; both groups underwent a second randomization to subsequent 13-cis-retinoic acid (cis-R) or no further therapy. The 3-year EFS rate among patients assigned to
transplantation was 43% and 27% among those assigned to continuation chemotherapy (p=0.027). However, OS rates for both groups did not differ significantly, with 3-year estimates of 43% or 44% for those assigned to transplant and continued chemotherapy, respectively (p=0.87).

Long-term results from this trial were reported in 2009 after a median follow-up of 7.7 years (range, 130 days to 12.8 years). The 5-year EFS rate for patients who underwent autologous transplant was 30% and 19% for those who underwent nonmyeloablative chemotherapy (p=0.04). Five-year OS rates from the second randomization of patients who underwent both random assignments were 59% for autologous transplant/cis-RA, 41% for autologous transplant/no cis-RA, and, for nonmyeloablative chemotherapy, 38% and 36% with and without cis-RA. Authors concluded that myeloablative chemotherapy and autologous HCT resulted in significantly better five-year EFS and OS rates.

Berthold et al (2005) randomized 295 patients with high-risk neuroblastoma to myeloablative therapy (melphalan, etoposide, carboplatin) plus autologous HCT or oral maintenance chemotherapy plus cyclophosphamide. The primary endpoint was EFS, with secondary endpoints of OS and treatment-related deaths. Intention-to-treat analysis showed that patients who received the myeloablative therapy had an increased 3-year EFS rate compared with the oral maintenance group (47% [95% CI, 38% to 55%] vs 31% [95% CI, 23% to 39%]), but did not have significantly increased 3-year OS rate (62% [95% CI, 54% to 70%] vs 53% [95% CI, 45% to 62%]; p=0.088). Two patients died from therapy-related complications during induction; no patients who received oral maintenance therapy died from treatment-related toxicity, and five patients who received myeloablative therapy died from acute complications related to the therapy.

Pritchard et al (2005) reported the results of a randomized, multicenter trial that involved 167 children with stage 3 or 4 neuroblastoma treated with standard induction chemotherapy who then underwent surgical resection of their tumor. Sixty-nine percent (n=90) of the patients who achieved complete response (CR) or partial response to the induction chemotherapy were eligible for randomization to HDC containing melphalan plus autologous HCT or to no further treatment. Seventy-two percent (n=65) of the eligible children were randomized, with 21 surviving at the time of the analysis (median follow-up, 14.3 years). A significant difference in the 5-year EFS and OS rates were seen in children older than 1 year of age with stage 4 disease (48 children with stage 4; 5-year EFS, 33% for HDC vs 17% for no further treatment; p=0.01).

Observational Studies

The use of HCT in patients with high-risk neuroblastoma has been supported in clinical practice. For example, Proust-Houdemont et al (2016) reported on a 30-year single-center series including 215 patients with stage 4, high-risk neuroblastoma treated with HDC (busulfan) with HCT. In this cohort, 5-year EFS and OS rates were 35.1% and 40%, respectively, and improved from baseline to the end of the reporting period.

Tandem Autologous HCT

Clinical Context and Therapy Purpose

The purpose of tandem autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with high-risk or relapsed peripheral neuroblastoma.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.
Patients
The relevant population of interest are individuals with high-risk or relapsed peripheral neuroblastoma.

Interventions
The therapy being considered is tandem autologous HCT.

Comparators
Comparators of interest include chemotherapy, single autologous HCT, targeted therapy, surgery, and radiotherapy.

Outcomes
The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

Timing
Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up at 24-, 38-, 56-, and 108- months is of interest for tandem autologous HCT to monitor relevant outcomes.

Setting
Patients with high-risk or relapsed peripheral neuroblastoma are actively managed by oncologists in an outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.

Nonrandomized Comparative Studies
Sung et al (2010) reported on a retrospective analysis of the efficacy of single vs tandem autologous HCT in patients older than 1 year of age newly diagnosed with stage 4 neuroblastoma from 2000 to 2005 who were enrolled in the Korean Society of Pediatric Hematology-Oncology registry. Patients were intended to receive a single (n=70) or tandem (n=71) autologous HCT at diagnosis; 57 and 59 patients underwent single and tandem transplantation as scheduled, respectively. Between groups, patient characteristics were similar except a higher proportion in the tandem group having bone metastases. Median follow-up was 56 months (range, 24-88 months) from diagnosis. Transplant-related mortality occurred in nine patients in the single transplant group and eight in the tandem group (two after the first transplant and six after the second). The intention-to-treat 5-year EFS rates for single and tandem were 31.3% and 51.2%, respectively (p=0.03). When the survival analysis only included patients who proceeded to transplant, the probability of relapse-free survival after the first transplant was higher in the tandem group (59.1%) than the single group (41.6%; p=0.099). The difference was statistically significant when the analysis focused on patients who did not achieve a CR before the first transplant.
(55.7% vs 0%, p=0.012). The authors concluded that tandem HCT for high-risk neuroblastoma is superior to single HCT regarding survival, particularly in patients without CR before HCT.

Ladenstein et al (2008) reported on more than 4000 transplants for primary (89%) and relapsed (11%) neuroblastoma over 28 years in 27 European countries in the European Group for Blood and Marrow Transplantation registry. Procedures included single autologous (n=2895), tandem autologous (n=455), and allogeneic HCT (n=71). Median age at the time of transplantation was 3.9 years (range, 0.3-62 years), with 77 patients older than age 18 years. Median follow-up from HCT was nine years. Transplant-related mortality decreased over time in registry patients who only received autologous transplants. Five-year OS rates were 37% for the autologous groups (single and tandem) and 25% for the allogeneic group. Five-year OS rates for single rate and tandem autologous HCT were 38% and 33%, respectively (p=0.105).

**Single-Arm Studies**

George et al (2006) reported on a 4-institution, single-arm clinical trial to evaluate tandem autologous HCT in pediatric patients with high-risk neuroblastoma (n=82) enrolled between 1994 and 2002. Median age at diagnosis was 35 months (range, 6 months to 18 years). Three- and 5-year OS rates were 74% (95% CI, 62% to 82%) and 64% (95% CI, 52% to 74%), respectively.

Kletzel et al (2002) reported on a single-center pilot study evaluating the outcomes for 25 consecutive newly diagnosed high-risk neuroblastoma patients and one with recurrent disease treated with triple-tandem autologous HCT. After stem cell rescue, patients were treated with radiotherapy to the primary site. Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Seventeen patients completed all three cycles of high-dose therapy and stem cell rescue, two patients completed two cycles, and three patients completed one cycle. One toxicity-related death occurred, and one patient died from complications of graft failure. Median follow-up was 38 months, and the 3-year EFS and OS rates were 57% and 79%, respectively.

Grupp et al (2000) reported on outcomes for a phase 2 trial involving 55 children with high-risk neuroblastoma who underwent tandem autologous HCT. Five patients completed the first HCT course but not the second. There were four toxicity-related deaths. With a median follow-up of 24 months from diagnosis, 3-year EFS was 59%.

**Case Series**

In a retrospective analysis of prospectively collected data, Pasqualini et al (2016) reported on a series of 26 patients with very high-risk neuroblastoma treated with tandem autologous HCT from 2004 to 2011 at a single-center. Criteria for “very high risk” included stage 4 neuroblastoma at diagnosis or relapse, age over one year at diagnosis, less than a partial response of metastases, and more than three metaiodobenzylguanidine spots after two lines of conventional chemotherapy in patients under ten years old or no CR of metastases after one line of conventional chemotherapy in patients over ten years old. Median age was 4.4 years (range, 1-15.9 years). Of the 26 patients, 22 were stage 4 at diagnosis; 4 patients had a stage 3 tumor at diagnosis and a metastatic relapse. Three-year EFS and OS rates after diagnosis were 37.3% (95% CI, 21.3% to 56.7%) and 69.0% (95% CI, 49.7% to 83.4%), respectively.

Kim et al (2007) retrospectively analyzed 36 patients with high-risk (stage 3 or 4) neuroblastoma who underwent a single autologous HCT (n=27) or a tandem autologous HCT (n=9) at a children’s hospital in Seoul, Korea, between 1996 and 2004. Disease-free survival of patients who underwent double HCT was similar to that of those who underwent a single autologous HCT (p=0.5).
Marcus et al (2003) reported on outcomes for 52 children with stage 4 or high-risk stage 3 neuroblastoma treated with induction chemotherapy, surgical resection of the tumor when feasible, local radiotherapy, and consolidation with tandem autologous HCT.\textsuperscript{38} Radiotherapy was given if gross or microscopic residual disease was present before the myeloablative cycles (n=37). Of the 52 consecutively treated patients analyzed, 44 underwent both transplants, 6 underwent a single transplant, and 2 progressed during induction. The 3-year EFS was 63%, with a median follow-up of 29.5 months.

Von Allmen et al (2005) reported on a retrospective series from the same center as Marcus et al (2003), with some overlap in patients.\textsuperscript{39} The updated series included 76 patients with previously untreated high-risk stage 3 or 4 neuroblastoma treated with aggressive surgical resection with or without local radiotherapy followed by tandem autologous HDC and stem cell rescue. Overall EFS for the series was 56%.

**Section Summary: Single Autologous and Tandem HCT for Peripheral Neuroblastoma**

No studies directly comparing single autologous HCT with tandem autologous HCT for high-risk neuroblastoma have been published. Randomized trials comparing single autologous HCT with conventional chemotherapy have reported EFS rates for the patients who underwent HCT ranging from 43% to 47% at 3 years and 30% at 5 years. Case series on the use of tandem autologous for high-risk neuroblastoma have reported 3-year EFS rates ranging from 57% to 63%. A retrospective analysis of a registry of patients with newly diagnosed high-risk neuroblastoma reported 5-year EFS rates for single and tandem autologous HCT of 31% and 51%, respectively (p=0.03).

**Ewing Sarcoma Family of Tumors**

**Single Autologous HCT**

**Clinical Context and Therapy Purpose**

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with high-risk Ewing sarcoma.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with high-risk Ewing sarcoma.

**Interventions**

The therapy being considered is single autologous HCT.

**Comparators**

Comparators of interest include chemotherapy, surgery, and radiotherapy.

**Outcomes**

The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

**Timing**
Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

**Setting**

Patients with high-risk Ewing sarcoma are managed by oncologists in both inpatient and outpatient clinical settings.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

During the 1980s and 1990s, several small series, case reports, and a report from the European Bone Marrow Transplant Registry suggested that autologous HCT could improve outcomes for patients with high-risk ESFT. These early results supported the use of HCT for high-risk ESFT.

Subsequently, Meyers et al (2001) reported on a prospective study with autologous HCT in 32 patients with newly diagnosed Ewing sarcoma metastatic to bone and/or bone marrow. Induction therapy consisted of five cycles of cyclophosphamide-doxorubicin-vincristine, alternating with ifosfamide-etoposide. Twenty-three patients proceeded to the consolidation phase with melphalan, etoposide, total body irradiation, and autologous HCT (of the nine patients who did not proceed, two were secondary to toxicity and four to progressive disease). Three patients died during the HDC phase. Two-year EFS for all eligible patients was 20% and 24% of the 29 patients who received the high-dose consolidation therapy. Trialists concluded that consolidation with HDC, total body irradiation, and autologous stem cell support failed to improve EFS for this cohort of patients compared with a similar group of patients treated with conventional therapy. Authors noted their findings differed from some previous studies and that the previous studies were limited by the inclusion of heterogeneous patient populations. They concluded that future trials of autologous HCT must be conducted prospectively, identify a group at high-risk for failure, and enroll all patients in the study at the same point in therapy.

Gardner et al (2008) reported on the results of 116 patients with Ewing sarcoma who underwent autologous HCT (80 as first-line therapy, 36 for recurrent disease) between 1989 and 2000. Five-year rates of progression-free survival in patients who received HCT as first-line therapy were 49% (95% CI, 30% to 69%) for those with localized disease at diagnosis and 34% (95% CI, 22% to 47%) for those with metastatic disease at diagnosis. For the population with localized disease at diagnosis and recurrent disease, the 5-year probability of PFS was 14% (95% CI, 3% to 30%). The authors concluded that PFS rates after autologous HCT were comparable with rates seen in patients with similar disease characteristics treated with conventional therapy.

Ladenstein et al (2010) reported on patients with primary disseminated multifocal Ewing sarcoma (PDMES) who were included in the Euro-EWING 99 trial. From 1999 to 2005, 281 patients with PDMES were enrolled in the Euro-EWING 99 R3 study; the Euro-EWING 99 committee stopped enrollment to this group and release the data. Median age was 16.2 years (range, 0.4-49 years). Patients
with isolated lung metastases were not part of the analysis. The recommended treatment consisted of induction chemotherapy, HDC, autologous HCT, and local treatment to the primary tumor (surgery and/or radiotherapy or neither). Induction therapy was completed by 250 (89%) of patients. One hundred sixty-nine (60%) of the patients proceeded to HCT. One patient died during induction therapy from sepsis. HDC TRM consisted of 3 patients dying within the first 100 days after high-dose therapy—1 from acute respiratory distress syndrome and 2 from severe veno-occlusive disease and septicemia; late deaths included 3 patients who died 1 to 1.5 years after high-dose therapy. After a median follow-up of 3.8 years, the estimated 3-year EFS and OS for all 281 patients were 27% and 34%, respectively.

**Tandem Autologous HCT**

**Clinical Context and Therapy Purpose**

The purpose of tandem autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with high-risk Ewing sarcoma.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with high-risk Ewing sarcoma.

**Interventions**

The therapy being considered is tandem autologous HCT.

**Comparators**

Comparators of interest include chemotherapy, single autologous HCT, surgery, and radiotherapy.

**Outcomes**

The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

**Timing**

Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

**Setting**

Patients with high-risk Ewing sarcoma are managed by oncologists in both the inpatient and outpatient clinical settings.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
d. Studies with duplicative or overlapping populations were excluded.

Loschi et al (2015) reported on a series of 18 patients with PDMES under age 25 treated with tandem HCT at a single institution from 2002 to 2009. Of the 18 patients with PDMES planned for tandem HCT, 15 (83%) received the first HCT, and 13 (72%) received the full-tandem HCT program, due to progressive disease before stem cell harvest could be obtained. Eleven patients had no disease progression by the end of the HCT program, but 9 of the 11 had relapsed, at a median delay of 6.2 months (range, 2.5-14.1 months). Median EFS and OS rates were 13.5 and 17.3 months, respectively.

Section Summary: Single Autologous and Tandem HCT for ESFT

Studies of HCT in patients with ESFT are characterized by small numbers of patients, and comparisons across studies were difficult for several reasons. Within each report, patients could have received a variety of chemotherapeutic regimens, and many studies did not share the same patient eligibility criteria (and in some, the definition of high-risk included patients with criteria that did not result in inferior prognosis). Also, some studies used allogeneic HCT. The risk-adjusted system used in Euro-EWING 99 may allow the best selection of patients appropriate for treatment.

Rhabdomyosarcoma

Clinical Context and Therapy Purpose

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with RMS.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest are individuals with RMS.

Interventions

The therapy being considered is single autologous HCT.

Comparators

Comparators of interest include chemotherapy, surgery, and radiotherapy.

Outcomes

The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

Timing

Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

Setting

Patients with RMS are managed by oncologists in both the inpatient and outpatient clinical settings.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.

Weigel et al (2001) reviewed and summarized published evidence on the role of autologous HCT in the treatment of metastatic or recurrent RMS from 22 studies (total n=389 patients). They concluded there was no significant advantage in undergoing this type of treatment.

McDowell et al (2010) reported on the results of the International Society of Paediatric Oncology study MMT-98, for pediatric patients from 48 centers with metastatic RMS entered into the study from 1998 to 2005. A total of 146 patients enrolled (age range, 6 months to 18 years). Patients were risk-stratified and treated accordingly. One hundred one patients were considered poor-risk (poor-risk group) if they were older than ten years of age or had bone marrow or bone metastases. Planned therapy for the poor-risk group was induction therapy, sequential HDC, peripheral blood autologous HCT, and maintenance therapy. Seventy-nine (78.2%) of the 101 poor-risk patients underwent the high-dose therapy, after which 67.1% achieved a PR or CR. Sixty-seven of the 101 poor-risk patients received local treatment-37 radiotherapy alone, 10 surgery alone, and 20 both modalities. No treatment-related deaths were reported in the poor-risk group. Three- and 5-year EFS rates for the poor-risk group were 16.5% and 14.9%, respectively, with 3- and 5-year OS rates of 23.7% and 17.9%, respectively (HR=2.46; 95% CI, 1.51 to 4.03; p<0.001).

Klingebiel et al (2008) prospectively compared the efficacy of 2, HDC treatments followed by autologous stem cell rescue with an oral maintenance treatment (OMT) in 96 children with stage 4 soft tissue sarcoma (88 of whom had RMS). Five-year OS probability for the whole group was 0.52 (standard deviation [SD]=0.14) for the patients who received OMT (n=51) and 0.27 (SD=0.13) for the transplant group (n=45; p=0.03). For the patients with RMS, 5-year OS probability was 0.52 (SD=0.16) with OMT and 0.15 (SD=0.12) with transplant (p=0.001). The authors concluded that the transplant failed to improve prognosis in metastatic soft tissue sarcoma but that OMT could be a promising alternative.

Carli et al (1999) conducted a prospective nonrandomized study of 52 patients with metastatic RMS, who were in CR after induction therapy and subsequently received HDC (megatherapy) and autologous HCT, and compared them with 44 patients who were in remission after induction therapy who subsequently received conventional chemotherapy. No significant differences existed between groups (ie, clinical characteristics, induction chemotherapy received, sites of primary tumor, histologic subtype, age, presence/extent of metastases). Three-year EFS and OS rates were 29.7% and 40%, respectively, for the autologous HCT group and 19.2% and 27.7%, respectively, for the chemotherapy group. Differences were not statistically significant for EFS (p=0.3) or OS (p=0.2). Median time to relapse after chemotherapy was 168 days for the autologous HCT group and 104 days for the standard chemotherapy group (p=0.05). Although the use of autologous HCT delayed time to relapse, there was no clear survival benefit compared with conventional chemotherapy.

Section Summary: RMS
Autologous HCT has been evaluated in a limited number of patients with high-risk RMS (stage 4 or relapsed) in whom CR was achieved after standard induction therapy. The evidence is relatively scarce, due in part to the rarity of the condition. The role of stem cell transplantation of any type for this cancer has not been established.

**Wilms Tumor**

**Clinical Context and Therapy Purpose**

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with Wilms tumor.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with Wilms tumor.

**Interventions**

The therapy being considered is single autologous HCT.

**Comparators**

Comparators of interest include chemotherapy, surgery, and radiotherapy.

**Outcomes**

The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

**Timing**

Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

**Setting**

Patients with Wilms tumor are managed by oncologists in both the inpatient and outpatient clinical settings.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.

A 2010 individual patient data meta-analysis reported on the efficacy of autologous HCT in recurrent Wilms tumor for studies published between 1984 and 2008 that reported survival data.\(^{49}\) Six studies were included (total n=100 patients).\(^{18,50,51,52,53,54}\) Patient characteristics and treatment methods were
similar across studies, although there was variation in the preparative regimens used. Patients were between the ages of 11 months and 16 years and had similar primary tumor stage, relapse location, and time to relapse. The 4-year OS rate among the 100 patients was 54.1% (95% CI, 42.8%-64.1%), and the 4-year EFS rate (based on 79 patients) was 50.0% (95% CI, 37.9%-60.9%). In multivariate analysis, site of relapse and histology were important predictors for survival; patients who did not have a lung-only relapse were at approximately three times higher risk of death or recurrence (HR=3.5) than patients who relapsed in the lungs only (HR=2.4), and the patients with unfavorable histology had approximately twice the risk of death compared with those with favorable histology. For all six studies, reviewers compared the survival rates for patients who received autologous HCT with patients who received conventional chemotherapy. In general, the chemotherapy-treated patients had similar or improved 4-year survival rates compared with the HCT group; however, there was a suggestion that patients with lung-only stage 3 and 4 relapses could benefit from autologous HCT; they had a 21.7% survival advantage over chemotherapy (however, the confidence interval ranges were very wide): 4-year OS rates for the stage 3 and 4 patients with lung-only relapse treated with HCT were 74.5% (95% CI, 51.7% to 87.7%) and 52.8% (95% CI, 29.7% to 71.5%) for chemotherapy.

Malogolowkin et al (2017) published a retrospective analysis describing the outcomes of 253 patients with relapsed Wilms tumor who received HDC followed by autologous HCT between 1990 and 2013 that were reported to the Center for International Blood and Marrow Transplant Research. The 5-year estimates for EFS and OS were 36% (95% CI; 29-43%) and 45% (95 CI; 38-51%), respectively. Relapse of primary disease was the cause of death in 81% of the population. EFS, OS, relapse, and transplant-related mortality showed no significant differences when broken down by disease status at transplant, time from diagnosis to transplant, year of transplant, or conditioning regimen. The data suggest that HDC followed by autologous HCT for relapsed Wilms tumor is well tolerated and outcomes are similar to those reported in the literature. The greatest limitation of the study is its retrospective, registry-based analyses and that the data originate from basic forms, and thus, did not include histology, site of metastases, stage of disease, genetic syndrome, tumor spillage, and radiation.

Section Summary: Wilms Tumor

The evidence on the use of autologous HCT for high-risk Wilms tumor consists of a retrospective analysis, small series, or case reports. For some subgroups-particularly patients with lung-only stage 3 and 4 relapses-some analyses have suggested that HCT could be associated with a survival benefit.

Osteosarcoma

Clinical Context and Therapy Purpose

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with osteosarcoma. The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)? The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest are individuals with osteosarcoma.

Interventions

The therapy being considered is single autologous HCT.
Comparators
Comparators of interest include chemotherapy, surgery, and radiotherapy.

Outcomes
The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

Timing
Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

Setting
Patients with osteosarcoma are managed by oncologists and orthopedic surgeons in both the inpatient and outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
d. Studies with duplicative or overlapping populations were excluded.

Venkatramani et al (2016) reported on outcomes from a protocol in which patients with newly diagnosed, biopsy-proven high-grade osteosarcoma with less than 90% tumor necrosis after preoperative chemotherapy were treated with 3 courses of HDC plus autologous HCT. The study enrolled 52 patients with localized osteosarcoma, most commonly of the femur (52%) from 1999 to 2006 who underwent definitive surgery; 6 patients withdrew prior to surgery, and 6 after surgery. Under the study’s initial protocol, those with less than 90% tumor necrosis were intended for HCT following HDC with melphalan and cyclophosphamide, and those with good tumor response were allocated to standard chemotherapy. However, after the first 18 patients received HCT, an interim analysis showed a 2-year EFS rate of 41%, which was less than the objective of 75% EFS compared with historical data of 55% by treating 48 patients with nonmetastatic disease who showed less than 90% necrosis following preoperative chemotherapy. Subsequently, all patients were enrolled in the standard therapy arm. Forty patients were evaluable after a median follow-up of 39 months. The 5-year EFS and OS rates were 62% (95% CI, 36% to 80%) and 74% (95% CI, 44% to 90%), respectively, for patients treated on the standard chemotherapy arm. The 5-year EFS and OS rates were 28% (95% CI, 10% to 49%) and 48% (95% CI, 23% to 69%), respectively, for patients treated on the HCT arm.

Hong et al (2015) reported on a retrospective series of 19 patients with high-risk osteosarcoma treated with autologous HCT at a single-center from 2006 to 2013. Median age at diagnosis was 11.8 years (range, 5.4-15.7 years). The indications for HCT were tumor necrosis less than 90% (n=8), initial metastasis (n=2), relapse (n=2), or a combination of tumor necrosis less than 90%, initial metastasis, and/or progression (n=6). At a mean follow-up of 31 months (range, 1-91 months), the OS rate was 78.3%, and the EFS rate was 67.4%. 

Original Policy Date: April 2000
Additional small series and case reports have examined the use of autologous HCT in osteosarcoma.\textsuperscript{58} Autologous HCT has been successful in inducing short-lasting remissions but has not shown an increase in survival.\textsuperscript{59}

**Section Summary: Osteosarcoma**

The evidence on the use of autologous HCT for treatment of osteosarcoma is limited to case series and a prospective single-arm study. An interim analysis of the single-arm study showed that patients receiving autologous HCT were experiencing lower EFS rates than historical controls, resulting in all patients enrolling in the standard of care chemotherapy arm for the remainder of the study.

**Retinoblastoma**

**Localized Retinoblastoma**

**Clinical Context and Therapy Purpose**

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with localized retinoblastoma.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with localized retinoblastoma.

**Interventions**

The therapy being considered is single autologous HCT.

**Comparators**

Comparators of interest include laser photocoagulation, cryotherapy, chemotherapy (local or systemic), surgery, and radiotherapy.

**Outcomes**

The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

**Timing**

Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

**Setting**

Patients with localized retinoblastoma are managed by oncologists in both the inpatient and outpatient clinical settings.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.

No studies focusing on autologous HCT for patients with localized retinoblastoma were identified in literature searches.

Metastatic Retinoblastoma

Clinical Context and Therapy Purpose

The purpose of single autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with metastatic retinoblastoma.

The question addressed in this evidence review is: does the use of autologous HCT improve the net health outcome in individuals with various pediatric-onset solid tumors (eg, blastomas, sarcomas)?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest are individuals with metastatic retinoblastoma.

Interventions

The therapy being considered is single autologous HCT.

Comparators

Comparators of interest include chemotherapy, surgery, and radiotherapy.

Outcomes

The general outcomes of interest are OS, DSS, TRM, and treatment-related morbidity.

Timing

Follow-up includes the immediate and 12-month posttransplant period to monitor for engraftment and other relevant outcomes. Follow-up will continue to be life-long depending on the success of single autologous HCT.

Setting

Patients with metastatic retinoblastoma are managed by oncologists in both the inpatient and outpatient clinical setting.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.
Most studies of autologous HCT for metastatic retinoblastoma have been very small series or case reports.\textsuperscript{60,61,62,63} More recently, Dunkel et al (2010) reported on outcomes for 15 consecutive patients with stage 4A metastatic retinoblastoma who presented between 1993 and 2006 and were treated with HDC and autologous HCT.\textsuperscript{64} Twelve patients had unilateral retinoblastoma, and three had bilateral disease. Metastatic disease was not detected at diagnosis but became clinically evident at a median of 6 months (range, 1-82 months) postenucleation. Patients had metastatic disease to bone marrow (n=14), bone (n=10), the orbit (n=9), and/or the liver (n=4). Two patients progressed before HCT and died. Thirteen patients underwent HCT, and 10 are retinoblastoma-free in first remission at a median follow-up of 103 months (range, 34-202 months). Three patients experienced recurrence 14 to 20 months postdiagnosis of metastatic disease, (2 in the central nervous system [CNS], 1 in the mandible), and all died of their disease. Five-year retinoblastoma-free survival and EFS rates were 67% (95% CI, 38% to 85%) and 59% (31% to 79%), respectively. Six of the ten patients who survived received radiotherapy. Three patients developed secondary osteosarcoma at 4, 9, and 14 years postdiagnosis of metastatic disease, 2 in previously irradiated fields, and 1 in a nonirradiated field. The authors concluded that HCT was curative for most patients treated in their study with stage 4A retinoblastoma.

Dunkel et al (2010) also reported on outcomes for 8 patients diagnosed with stage 4B retinoblastoma between 2000 and 2006 treated with the intention of autologous HCT.\textsuperscript{22} Seven patients had leptomeningeal disease and one had only direct extension to the CNS via the optic nerve. At the time of diagnosis of intraocular retinoblastoma, 3 patients already had stage 4B disease; the other 5 patients developed metastatic disease at a median of 12 months (range, 3-69 months). Two patients progressed before HCT, and one patient died due to toxicity during induction chemotherapy. Of the 5 patients who underwent HCT, 2 are event-free at 40 and 101 months. One of the event-free survivors received radiotherapy (external-beam plus intrathecal radioimmunotherapy), and the other did not receive any radiotherapy. Three patients had tumor recurrence at three, seven, and ten months post-HCT. The authors concluded that HCT could be beneficial for some patients with stage 4B retinoblastoma, but longer follow-up would be necessary to determine whether it is curative in this population.

\textbf{Section Summary: Localized and Metastatic Retinoblastoma}

There is a lack of evidence evaluating the use of autologous HCT for localized retinoblastoma. The results have been promising regarding prolonging disease-free survival in patients with metastatic retinoblastoma, particularly those without CNS involvement (stage 4A). Given that clinical prognosis is very poor for patients with metastases, results showing the survival of some patients for three or more years after HCT might provide evidence to demonstrate a benefit in survival. The role of stem cell transplantation has not been established in the therapy of patients with localized retinoblastoma.

\textbf{Comparative Effectiveness Review}

The Blue Cross and Blue Shield Association (2012) prepared a comparative effectiveness review on the use of HCT in the pediatric population for the Agency for Healthcare Research and Quality.\textsuperscript{65} The following conclusions were offered:

- \textbf{Neuroblastoma:} The body of evidence on OS with tandem HCT compared with single HCT for the treatment of high-risk neuroblastoma was insufficient to draw conclusions.

- \textbf{ESFT:} The low-strength evidence on OS suggested no benefit with single HCT compared with conventional therapy for the treatment of high-risk ESFT.
  - The body of evidence on OS with tandem HCT compared with single HCT for the treatment of high-risk ESFT and OS was insufficient to draw conclusions.
• RMS: The moderate-strength evidence on OS suggested no benefit with single HCT compared with conventional therapy for the treatment of high-risk metastatic RMS.
  o The body of evidence on OS with single HCT compared with conventional therapy for the treatment of high-risk RMS of mixed tumor type was insufficient to draw conclusions.
  o The body of evidence on OS with single HCT compared with conventional therapy for the treatment of congenital alveolar RMS, cranial parameningeal RMS with metastasis or the use of allogeneic transplantation for metastatic RMS was insufficient to draw conclusions.

• Wilms tumor: The low-strength evidence on OS suggested no benefit with single HCT compared with conventional therapy for the treatment of high-risk relapsed Wilms tumor.

• Osteosarcoma was not addressed.

• Retinoblastoma: The low-strength evidence on OS suggested no benefit with single HCT compared with conventional therapy for the treatment of extraocular retinoblastoma with CNS involvement.
  o The body of evidence on OS with single HCT compared with conventional therapy for the treatment of extraocular retinoblastoma without CNS involvement was insufficient to draw conclusions.
  o The body of evidence on OS with single HCT compared with conventional therapy for the treatment of trilateral retinoblastoma without CNS involvement was insufficient to draw conclusions.

Summary of Evidence

For individuals who have high-risk or relapsed peripheral neuroblastoma who receive single or tandem autologous HCT, the evidence includes RCTs, systematic reviews of those trials, and observational studies. The relevant outcomes are OS, DSS, and TRM and morbidity. In the pooled analysis, patients with high-risk neuroblastoma treated with first-line therapy with single autologous HCT with myeloablative conditioning had significantly improved EFS compared with standard therapy. Similarly, well-designed randomized trials comparing tandem autologous HCT with conventional therapy showed improvements in EFS for children with high-risk neuroblastoma. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have high-risk or relapsed peripheral neuroblastoma who receive single or tandem autologous HCT, the evidence includes randomized controlled trials, systematic reviews of those trials, and observational studies. The relevant outcomes are overall survival (OS), disease-specific survival (DSS), and treatment-related mortality (TRM) and morbidity. In the pooled analysis, patients with high-risk neuroblastoma treated with first-line therapy with single autologous HCT with myeloablative conditioning had significantly improved event-free survival (EFS) compared with standard therapy. Similarly, well-designed randomized trials comparing tandem autologous HCT with conventional therapy showed improvements in EFS for children with high-risk neuroblastoma. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have high-risk Ewing sarcoma who receive single or tandem autologous HCT, the evidence includes single-arm studies. The relevant outcomes are OS, DSS, and TRM and morbidity. Although early nonrandomized studies were promising, more recent prospective nonrandomized study...
results have been inconsistent regarding whether HCT extends survival compared with typical conventional therapy. Additional studies, including a randomized trial, are ongoing, comparing HCT with conventional therapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2011 supported the use of single autologous HCT for high-risk Ewing sarcoma, and it is supported by national guidelines from the American Society for Blood and Marrow Transplantation. Also, the use of single autologous HCT is supported by national guidelines for recurrent or refractory Ewing sarcoma. Therefore, autologous HCT may be considered medically necessary for these indications.

For individuals who have rhabdomyosarcoma who receive single autologous HCT, the evidence includes nonrandomized comparative studies and case series. The relevant outcomes are OS, DSF, and TRM and morbidity. Available studies have not demonstrated improvements in OS or EFS with autologous HCT. Additional research is needed to demonstrate a benefit with autologous HCT for pediatric rhabdomyosarcoma. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have Wilms tumor who receive single autologous HCT, the evidence includes a retrospective analysis, meta-analysis of case series, and case reports. The relevant outcomes are OS, DSS, and TRM and morbidity. Overall four-year survival rates were similar between patients receiving HCT and receiving chemotherapy. There was a trend suggesting that patients with lung-only stage 3 or 4 relapse might benefit from autologous HCT. However, the overall body of evidence is limited. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2017 does not support whether the following indication provides a clinically meaningful improvement in the net health outcome or is consistent with generally accepted medical practice:

- Use of autologous HCT for children with advanced-stage Wilms tumor.

Thus, the above indication may be considered investigational.

For individuals who have osteosarcoma who receive single autologous HCT, the evidence includes case reports, case series, and a prospective single-arm study. The relevant outcomes are OS, DSF, and TRM and morbidity. An interim analysis of the prospective single-arm study showed that patients receiving autologous HCT were experiencing lower EFS rates than historical controls, resulting in all patients being enrolled in the standard of care chemotherapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2017 does not support whether the following indication provides a clinically meaningful improvement in the net health outcome or is consistent with generally accepted medical practice:

- Use of autologous HCT for children with osteosarcoma.

Thus, the above indication(s) may be considered investigational.

For individuals who have localized retinoblastoma who receive single autologous HCT, the evidence includes no studies. The relevant outcomes are OS, DSS, and TRM and morbidity. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have metastatic retinoblastoma who receive single autologous HCT, the evidence includes small case series and case reports and a systematic review and meta-analysis.
The relevant outcomes are OS, DSS, and TRM and morbidity. Results from the limited data have suggested that autologous HCT may prolong disease-free survival, particularly in patients without central nervous system involvement (stage 4A). Given the poor prognosis for this indication with conventional therapies, the incremental improvement with autologous HCT might be considered a significant benefit. However, the overall body of evidence is limited. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2017 supports that the following indication provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice:

- Use of autologous HCT for children with metastatic retinoblastoma.

Thus, the above indication may be considered medically necessary considering the suggestive evidence and clinical input support.

**Clinical Input Responses**

**Figure1:**

**Additional Comments**

Both clinical experts acknowledged that the current evidence is quite limited, given the small number of studies and patients.

- “It is important to recognize how rare some of these cancers, and particular indications are. For example, there are only 200-300 new cases of retinoblastoma diagnosed each year. The number of those that would be considered metastatic, would be significantly lower (<10%). Due to these small numbers, the chance of performing the gold standard randomized controlled clinical trial of transplant vs chemo and/or radiation is nearly impossible.” (Dr. Kitko)

- “Metastatic retinoblastoma: the current evidence is just not enough to make any good conclusions-small numbers of studies/patients” (Dr. Yankelevich)

- “Osteosarcoma showed absolutely no evidence for any role of high dose chemotherapy.” (Dr. Yankelevich)

- Furthermore, the rare clinical context of these conditions may be considered.

- “While the amount of data is limited regarding the role of autologous stem cell transplant in this setting [ie, metastatic retinoblastoma], the small case reports and case series show a signal that outcomes may be improved with this aggressive treatment approach.” (Dr. Kitko)

- “Similar with Wilms tumor, modern chemotherapy regimens provide excellent long-term survival, therefore, the numbers of patients with recurrent disease are extremely small, making quality clinical trials very difficult to design. Evidence would indicate that there may be a signal that high dose chemotherapy followed by autologous stem cell transplant may provide improved survival in certain high risk groups, such as those with isolated pulmonary recurrence.” (Dr. Kitko)

See Appendices 1 and 2 for details of the 2017 clinical input.

**SUPPLEMENTAL INFORMATION**

**Clinical Input from Physician Specialty Societies and Academic Medical Centers**
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2017 Input

In response to requests, clinical input on autologous hematopoietic cell transplantation (HCT) for children with metastatic retinoblastoma, advanced-stage Wilms tumor, and osteosarcoma was received from 2 respondents, including 2 physicians from academic centers, while this policy was under review in 2017.

Based on the evidence and independent clinical input, the clinical input supports that the following indications provide a clinically meaningful improvement in the net health outcome and are consistent with generally accepted medical practice:

- Use of autologous HCT for children with metastatic retinoblastoma.

Based on the evidence and independent clinical input, the clinical input does not support whether the following indications provide a clinically meaningful improvement in the net health outcome or are consistent with generally accepted medical practice:

- Use of autologous HCT for children with advanced-stage Wilms tumor.
- Use of autologous HCT for children with osteosarcoma.

2011 Input

In response to requests, input was received from 3 academic medical centers and 2 Blue Distinction Centers for Transplants for review in 2011. There was general agreement among reviewers for most of the policy statements with the following exceptions. One reviewer considered autologous HCT medically necessary for advanced-stage retinoblastoma. One reviewer did not consider autologous HCT for low- to intermediate-risk Ewing sarcoma investigational but did state that the results of the Euro-EWING’s phase 3 trial were awaited. Two reviewers agreed with the policy statement that tandem autologous HCT for pediatric solid tumors is investigational, two considered it medically necessary for high-risk neuroblastoma, and a fifth reviewer while agreeing that tandem autologous HCT is considered investigational for pediatric solid tumors also stated that it is considered standard for high-risk neuroblastoma at some centers.

Practice Guidelines and Position Statements

American Society for Blood and Marrow Transplantation

The American Society for Blood and Marrow Transplantation (2015) published consensus guidelines for clinically appropriate indications for HCT based on best prevailing evidence.\(^66\) Indications for HCT in pediatric patients with the solid tumors types addressed in this review are outlined in Table 4.

Table 4. Indications for HCT in Pediatric Patients with Solid Tumors

<table>
<thead>
<tr>
<th>Indication and Disease Status</th>
<th>Allogeneic HCT(^a)</th>
<th>Autologous HCT(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ewing sarcoma, high risk or relapse</td>
<td>D</td>
<td>S</td>
</tr>
<tr>
<td>Soft tissue sarcoma, high risk or relapse</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Neuroblastoma, high risk or relapse</td>
<td>D</td>
<td>S</td>
</tr>
</tbody>
</table>
Wilms tumor, relapse  N  C
Osteosarcoma, high risk  N  C

Adapted from Majhail et al (2015). 66
HCT: hematopoietic cell transplantation.

“Standard of care (S): This category includes indications that are well defined and are generally supported by evidence in the form of high quality clinical trials and/or observational studies (eg, through CIBMTR or EBMT).” “Standard of care, clinical evidence available (C): This category includes indications for which large clinical trials and observational studies are not available. However, HCT has been shown to be an effective therapy with acceptable risk of morbidity and mortality in sufficiently large single- or multi-center cohort studies. HCT can be considered as a treatment option for individual patients after careful evaluation of risks and benefits. As more evidence becomes available, some indications may be reclassified as ‘Standard of Care’.” “Developmental; (D): Developmental indications include diseases where pre-clinical and/or early phase clinical studies show HCT to be a promising treatment option. HCT is best pursued for these indications as part of a clinical trial. As more evidence becomes available, some indications may be reclassified as ‘Standard of Care, Clinical Evidence Available’ or ‘Standard of Care’.” “Not generally recommended (N): Transplantation is not currently recommended for these indications where evidence and clinical practice do not support the routine use of HCT. The effectiveness of non-transplant therapies for an earlier phase of a disease does not justify the risks of HCT. Alternatively, a meaningful benefit is not expected from the procedure in patients with an advanced phase of a disease. However, this recommendation does not preclude investigation of HCT as a potential treatment and transplantation may be pursued for these indications within the context of a clinical trial.”

National Comprehensive Cancer Network

Current National Comprehensive Cancer Network guidelines or comments on HCT related to the cancers addressed in this review are summarized in Table 5. Other tumor types are not addressed in Network guidelines.

Table 5. NCCN Guidelines

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Tumor Type</th>
<th>Year</th>
<th>NCCN Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone cancer</td>
<td>Osteosarcoma</td>
<td>v.1.2018</td>
<td>HCT not addressed</td>
</tr>
<tr>
<td>Bone cancer</td>
<td>Ewing sarcoma</td>
<td>v.1.2018</td>
<td>“High dose chemotherapy followed by stem cell transplant (HDT/SCT) has been evaluated in patients with localized as well as metastatic disease. HDT/SCT has been associated with potential survival benefit in patients with non-metastatic disease. However, studies that have evaluated HDT/SCT in patients with primary metastatic disease have shown conflicting results.... HDT/SCT has been associated with improved long-term survival in patients with relapsed or progressive Ewing sarcoma in small, single-institution studies. The role of this approach is yet to be determined in prospective randomized studies.”</td>
</tr>
<tr>
<td>Soft tissue</td>
<td>Rhabdomyosarcoma</td>
<td>v.1.2018</td>
<td>HCT not addressed</td>
</tr>
</tbody>
</table>
Hematopoietic Cell Transplantation for Solid Tumors of Childhood

sarcoma

HCT: hematopoietic cell transplantation; NCCN: National Comprehensive Cancer Network.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this policy are listed in Table 6.

Table 6. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined solid tumor</td>
<td>Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors</td>
<td>25</td>
<td>Jun 2019</td>
</tr>
<tr>
<td>Peripheral neuroblastoma</td>
<td>High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)</td>
<td>3300</td>
<td>Sep 2024 (ongoing)</td>
</tr>
<tr>
<td>Ewing sarcoma</td>
<td>Phase 3, Open Label, Multi-centre, Randomized Controlled International Study in Ewing Sarcoma</td>
<td>1163</td>
<td>Mar 2019</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma</td>
<td>60</td>
<td>Jun 2018</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

ESSENTIAL HEALTH BENEFITS

The Affordable Care Act (ACA) requires fully insured non-grandfathered individual and small group benefit plans to provide coverage for ten categories of Essential Health Benefits (“EHBs”), whether the benefit plans are offered through an Exchange or not. States can define EHBs for their respective state.

States vary on how they define the term small group. In Idaho, a small group employer is defined as an employer with at least two but no more than fifty eligible employees on the first day of the plan or contract year, the majority of whom are employed in Idaho. Large group employers, whether they are self-funded or fully insured, are not required to offer EHBs, but may voluntary offer them.
The Affordable Care Act requires any benefit plan offering EHBs to remove all dollar limits for EHBs.

REFERENCES

German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. Feb 1997;19(3):227-231. PMID 9028550


**CODES**

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204</td>
<td>Management of recipient hematopoietic cell donor search and cell acquisition</td>
</tr>
<tr>
<td></td>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic</td>
</tr>
<tr>
<td></td>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, autologous</td>
</tr>
<tr>
<td></td>
<td>38207</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td></td>
<td>38208</td>
<td>Thawing of previously frozen harvest, without washing, per donor</td>
</tr>
<tr>
<td></td>
<td>38209</td>
<td>Thawing of previously frozen harvest with washing, per donor</td>
</tr>
<tr>
<td></td>
<td>38210</td>
<td>Specific cell depletion with harvest, T cell depletion</td>
</tr>
<tr>
<td></td>
<td>38211</td>
<td>Tumor cell depletion</td>
</tr>
<tr>
<td></td>
<td>38212</td>
<td>Red blood cell removal</td>
</tr>
<tr>
<td></td>
<td>38213</td>
<td>Platelet depletion</td>
</tr>
<tr>
<td></td>
<td>38214</td>
<td>Plasma (volume) depletion</td>
</tr>
<tr>
<td></td>
<td>38215</td>
<td>Cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
<tr>
<td></td>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td></td>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td></td>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td></td>
<td>38241</td>
<td>Autologous transplantation</td>
</tr>
<tr>
<td></td>
<td>86812-86821</td>
<td>Histocompatibility studies code range (eg, for allogeneic</td>
</tr>
<tr>
<td>HCPCS</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Q0083-Q0085</td>
<td>Chemotherapy administration code range,</td>
<td></td>
</tr>
<tr>
<td>J9000-J9999</td>
<td>Chemotherapy drugs code range</td>
<td></td>
</tr>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation, allogeneic</td>
<td></td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood-derived stem-cell transplantation, allogeneic</td>
<td></td>
</tr>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C41.0-C41.1</td>
<td>Malignant neoplasm of bones of skull, face and mandible; code range</td>
</tr>
<tr>
<td>C49.0</td>
<td>Malignant neoplasm of connective and soft tissue of head, face and neck</td>
</tr>
<tr>
<td>C64.1-C64.9</td>
<td>Malignant neoplasm of kidney, except renal pelvis; code range</td>
</tr>
<tr>
<td>C69.20-C69.22</td>
<td>Malignant neoplasm of retina; code range</td>
</tr>
<tr>
<td>C74.90-C74.92</td>
<td>Malignant neoplasm of adrenal gland, unspecified; code range</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30243G0, 30243X0, 30243Y0</td>
<td>Administration, circulatory, transfusion, central vein, percutaneous, autologous, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>30243G2, 30243X2, 30243Y2</td>
<td>Administration, circulatory, transfusion, central vein, percutaneous, allogeneic related, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>30243G3, 30243X3, 30243Y3</td>
<td>Administration, circulatory, transfusion, central vein, percutaneous, allogeneic unrelated, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>30243G4, 30243X4, 30243Y4</td>
<td>Administration, circulatory, transfusion, central vein, percutaneous, allogeneic unspecified, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>30233G0, 30233X0, 30233Y0</td>
<td>Administration, circulatory, transfusion, peripheral vein, percutaneous, autologous, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>30233G2, 30233X2, 30233Y2</td>
<td>Administration, circulatory, transfusion, peripheral vein, percutaneous, allogeneic related, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>30233G3, 30233X3, 30233Y3</td>
<td>Administration, circulatory, transfusion, peripheral vein, percutaneous, allogeneic unrelated, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>30233G4, 30233X4, 30233Y4</td>
<td>Administration, circulatory, transfusion, peripheral vein, percutaneous, allogeneic unspecified, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
<tr>
<td>3E03005, 3E03305</td>
<td>Introduction of other antineoplastic into peripheral vein, code by approach</td>
</tr>
<tr>
<td>3E04005, 3E04305</td>
<td>Introduction of other antineoplastic into central vein, code by approach</td>
</tr>
<tr>
<td>3E05005, 3E05305</td>
<td>Introduction of other antineoplastic into peripheral artery, code by approach</td>
</tr>
<tr>
<td>3E06005, 3E06305</td>
<td>Introduction of other antineoplastic into central artery, code by approach</td>
</tr>
<tr>
<td>30230AZ, 30233AZ</td>
<td>Transfusion of stem cells, embryonic into peripheral vein, code by approach</td>
</tr>
<tr>
<td>07DQ0ZZ, 07DQ3ZZ</td>
<td>Extraction of sternum bone marrow, code by approach</td>
</tr>
<tr>
<td>07DR0ZZ, 07DR3ZZ</td>
<td>Extraction of iliac bone marrow, code by approach</td>
</tr>
<tr>
<td>07DS0ZZ, 07DS3ZZ</td>
<td>Extraction of vertebral bone marrow, code by approach</td>
</tr>
<tr>
<td>6A550ZT, 6A551ZT</td>
<td>Pheresis of cord blood stem cells, code for single or multiple</td>
</tr>
<tr>
<td>6A550ZV, 6A551ZV</td>
<td>Pheresis of hematopoietic stem cells, code for single or multiple</td>
</tr>
</tbody>
</table>

**Type of service:** Therapy  
**Place of service:** Inpatient/Outpatient

### POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/10/14</td>
<td>Replace policy</td>
<td>Policy updated with literature review through March 2014; reference 23 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>04/23/15</td>
<td>Replace policy</td>
<td>Policy updated with literature review through March 4, 2015; reference 54 added; 55 updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>02/24/17</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho annual review; no change to policy.</td>
</tr>
<tr>
<td>06/01/17</td>
<td>Replace policy</td>
<td>Policy updated with literature review through November 9, 2016; references 1, 3, 13, 20-21, 23, 28, 30, 36, 44, 55-56, and 65-67 added. Changed “hematopoietic stem cell transplantation” to “hematopoietic cell transplantation” per NCCN terminology change. Clinical input added. Based on clinical input, “metastatic retinoblastoma” added to first medically necessary statement. In</td>
</tr>
</tbody>
</table>
first investigational statement, ‘retinoblastoma’ changed to “retinoblastoma without metastases.”

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/26/18</td>
<td>Replace policy</td>
<td>Policy updated with literature review through November 7, 2017; no references added. Policy statements unchanged.</td>
</tr>
<tr>
<td>01/24/19</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted, effective 01/24/2019. Policy updated with literature review through October 29, 2018; reference 55 added. Policy statements unchanged.</td>
</tr>
</tbody>
</table>
APPENDIX

Appendix 1. Clinical Input 2017

Appendix Table 1. Respondent Profile

<table>
<thead>
<tr>
<th>No.</th>
<th>Name</th>
<th>Degree</th>
<th>Organization</th>
<th>Clinical Specialty</th>
<th>Board Certification and Fellowship Training</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Kitko, Carrie L.</td>
<td>MD</td>
<td>Vanderbilt University Medical Center</td>
<td>Pediatric Hematology/Oncology, BMT</td>
<td>Pediatric hematology/oncology; Fellowship training at University of Michigan</td>
</tr>
<tr>
<td>2</td>
<td>Yankelevich, Maxim</td>
<td>MD</td>
<td>Wayne State University, Department of Pediatrics, Children's Hospital of MI</td>
<td>Pediatric Hematology/Oncology, BMT</td>
<td>Pediatrics, Pediatric hematology/oncology</td>
</tr>
</tbody>
</table>

Appendix Table 2. Respondent Conflict of Interest Disclosure

<table>
<thead>
<tr>
<th>No.</th>
<th>Yes/No</th>
<th>Explanation</th>
<th>Yes/No</th>
<th>Explanation</th>
<th>Yes/No</th>
<th>Explanation</th>
<th>Yes/No</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No</td>
<td></td>
<td>Yes</td>
<td>I am employed by Vanderbilt University Medical Center as a pediatric bone marrow transplant physician.</td>
<td>No</td>
<td></td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
Hematopoietic Cell Transplantation for Solid Tumors of Childhood

perform several of these types of transplants each year.

Objective
Clinical input is sought to help determine the appropriate use in clinical practice of hematopoietic cell transplantation (HCT) for children who have metastatic retinoblastoma, late-stage Wilms tumor, or osteosarcoma.

Responses
1. With regard to use of HCT for children who have metastatic retinoblastoma:
   a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that there is adequate evidence demonstrating that this use will improve health outcomes.

<table>
<thead>
<tr>
<th>No.</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

   b. Please use the 1 to 5 scale outlined below to indicate your level of confidence that this clinical use is in accordance with generally accepted medical practice.

<table>
<thead>
<tr>
<th>No.</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
1. With regard to use of HCT for children who have late-stage Wilms tumor:
   a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that there is adequate evidence demonstrating that this use will improve health outcomes.

<table>
<thead>
<tr>
<th>No.</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

2. With regard to use of HCT for children who have osteosarcoma:
   a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that there is adequate evidence demonstrating that this use will improve health outcomes.

<table>
<thead>
<tr>
<th>No.</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

3. With regard to use of HCT for children who have osteosarcoma:
   a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that this clinical use is in accordance with generally accepted medical practice.

<table>
<thead>
<tr>
<th>No.</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
Hematopoietic Cell Transplantation for Solid Tumors of Childhood

2 X

b. Please use the 1 to 5 scale outlined below to indicate your level of confidence that this clinical use is in accordance with generally accepted medical practice.

<table>
<thead>
<tr>
<th>No.</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>X</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Additional comments and/or any citations supporting your clinical input on the use of HCT for children who have metastatic retinoblastoma, late-stage Wilms tumor, or osteosarcoma.

<table>
<thead>
<tr>
<th>No.</th>
<th>Additional Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>It is important to recognize how rare some of these cancers, and particular indications are. For example, there are only 200-300 new cases of retinoblastoma diagnosed each year. The number of those that would be considered metastatic, would be significantly lower (&lt;10%). Due to these small numbers, the chance of performing the gold standard randomized controlled clinical trial of transplant vs chemo and/or radiation is nearly impossible. While the amount of data is limited regarding the role of autologous stem cell transplant in this setting, the small case reports and case series show a signal that outcomes may be improved with this aggressive treatment approach. Similar with Wilms tumor, modern chemotherapy regimens provide excellent long-term survival, therefore, the numbers of patients with recurrent disease are extremely small, making quality clinical trials very difficult to design. Evidence would indicate that there may be a signal that high dose chemotherapy followed by autologous stem cell transplant may provide improved survival in certain high risk groups, such as those with isolated pulmonary recurrence</td>
</tr>
<tr>
<td>2</td>
<td>Metastatic retinoblastoma: the current evidence is just not enough to make any good conclusions -small numbers of studies/patients Wilms tumor: it appears that patients with favorable histology/isolated pulmonary recurrences can achieve 50-60% survival rates with intensive second line conventional chemotherapy containing alkylating agents, etoposide, carboplatin. Wilms patients commonly have a single kidney when they relapse making high dose chemo more risky in terms of acute renal failure from high dose carboplatin. Osteosarcoma showed absolutely no evidence for any role of high dose chemotherapy</td>
</tr>
</tbody>
</table>
5. Is there any evidence missing from the attached draft review of evidence?

<table>
<thead>
<tr>
<th>No.</th>
<th>Yes/No</th>
<th>Citations of Missing Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>